Latest Europe News

OncoSil Medical has achieved a key regulatory milestone with MDR certification from BSI, removing post-market restrictions and streamlining its commercial operations across Europe. This approval also paves the way for renewed efforts to enter the Australian market.

Cosmos Exploration has secured an exclusive option to acquire EAU Lithium, partnering with Vulcan Energy to deploy cutting-edge Direct Lithium Extraction technology in Bolivia’s lithium-rich salars. This strategic move positions Cosmos at the forefront of sustainable lithium production in the world’s largest lithium resource base.

Bioxyne Limited has reported a remarkable 77% jump in revenue for Q2 FY2025, alongside positive operating cash flow, as it prepares to expand manufacturing capacity and enter new international markets.

Zeotech Limited has secured a strategic MOU with Holcim Australia to advance its AusPozz™ low-carbon concrete product, alongside promising methane reduction results and a newly granted Japanese patent.

Hydrix Limited reports back-to-back profitable quarters driven by strong margins and cost efficiencies, underpinned by a robust $40 million sales opportunity pipeline in cardiac and medtech sectors.

Bioxyne Limited reports a remarkable 77% revenue increase in Q2 FY2025 alongside positive operating cash flow, setting the stage for international growth with upcoming UK export approvals and a planned European GMP facility.

Aura Energy has reported a substantial 49% increase in Ore Reserves at its flagship Tiris Uranium Project, advancing towards a Final Investment Decision in early 2025 while also benefiting from positive regulatory shifts in Sweden.

Sprintex has locked in A$30 million in distribution agreements across the UK, Turkiye, and India, while advancing its innovative G25 Jet Blower launch, signaling a strong growth trajectory in energy-efficient technologies.

Dimerix Limited has inked a lucrative licensing agreement with Fuso Pharmaceutical for its kidney disease drug DMX-200 in Japan, while completing recruitment for its pivotal Phase 3 ACTION3 trial.

Zelira Therapeutics has received a fourth funding tranche, bringing total investment to US$3.25 million to support FDA clinical trials of its HOPE® 1 cannabinoid medicine targeting irritability in autism spectrum disorder and Phelan-McDermid Syndrome.

Phoslock Environmental Technologies reported a widening cashflow deficit and disappointing sales in the December 2024 quarter, while legal challenges and share suspension continue to cloud its outlook.

Infinity Lithium updates on regulatory feedback delaying its San José mining licence and pivots to larger European funding opportunities, signaling a strategic shift in project development.